Friday, May 16, 2025
TimeNews
  • Automotive
  • Beauty
  • Business
  • Health
  • Real estate
No Result
View All Result
TimeNews
  • Automotive
  • Beauty
  • Business
  • Health
  • Real estate
No Result
View All Result
TimeNews
No Result
View All Result

Antibody Drug Conjugate Market: Advances in Antibody Drug Conjugate Technology

Home Health

Target-specific therapies are reshaping the healthcare landscape, providing a promising solution to treat cancer. The therapies involve monoclonal antibodies that induce the immune system to initiate an action against infection and disease, thereby killing the cells. Despite its significant role in cancer treatment, monoclonal antibodies have low binding efficiency and lead to toxicity in normal cells. To address the concern, antibody-drug conjugate emerges as the next-generation target-specific therapy for the treatment of cancer. It combines small molecule cytotoxin, monoclonal antibodies, and linkers that efficiently deliver the cytotoxin inside the tumor cells without causing damage to normal cells.

To date, the approved ADCs have been used for the treatment of urothelial cancer, cervical cancer, multiple myeloma, ovarian cancer, and breast cancer. The increasing number of patients with cancer at the global level raises concern about finding more antibody-drug conjugates for the treatment. Around 14 antibody-drug conjugates are approved by the FDA for the treatment of cancer. Besides this, the ADC market players, including Pfizer and Seagen, are actively engaged in developing more ADCs by leveraging advanced technologies and genetic engineering. Driven by the above factors, it is expected that the global Antibody drug conjugate market will grow at a CAGR of 9.63% in the future, according to Roots Analysis.

Antibody Drug Conjugates- The New Frontier of Cancer Treatment

Antibody drug conjugates have a potent cytotoxic anticancer agent, which is linked to the antibody via a biodegradable linker. The antibodies bind directly to the specific antigens or receptors available at the surface of cancerous cells. Antibody-drug conjugate formed with the linker internalized into the cancer cell and released the drug. The mechanism of action of ADC is simple and focused on delivering cytotoxic agents inside the tumor cells, maximizing the therapeutic index, and reducing exposure to normal tissues. The cell lysis begins when ADC reaches the target site and releases the payload.

Antibody Drug Conjugates Approved For the Treatment 

The targeted delivery of cytotoxic compounds into the tumor cells is a strategic approach to treating cancerous patients. However, the development of antibody-drug conjugates poses considerable challenges for the antibody-drug conjugate market players. With persistent research and technological advances, several market players, including Pfizer, Seattle Genetics, and more, have successfully secured approval of the below-listed ADCs from the FDA.

Table: List of Antibody Drug Conjugates Approved By FDA For The Treatment

Company Name

Trade name

ADC Drug

Target

Payload Action

ImmunoGen

ELAHERE®

Mirvetuximab soravtansine

FRα

Folate receptor alpha

Seagen

Tivdak®

Tisotumab vedotin-tftv

Tissue factor

microtubule inhibitor

Seagen

Tivdak®

Tisotumab vedotin-tftv

Tissue factor

microtubule inhibitor

ADC Therapeutics

Zynlonta®

Loncastuximab tesirine-lpyl

CD19

DNA cleavage

Immunomedics

Trodelvy®

Sacituzumab govitecan

TROP2

TOP1 inhibitor

AstraZeneca/Daiichi Sankyo

Enhertu®

Trastuzumab deruxtecan

HER2

TOP1 inhibitor

Astellas/Seagen Genetics

Padcev®

Enfortumab vedotin

Nectin4

microtubule inhibitor

Genentech, Roche

Polivy™

Polatuzumab vedotin-piiq

CD79

microtubule inhibitor

Astrazeneca

Lumoxiti®

Moxetumomab pasudotox

CD22

–

Pfizer/Wyeth

Besponsa®

Inotuzumab ozogamicin

CD22

DNA cleavage

Genentech, Roche

Kadcyla®

Trastuzumab emtansine

HER2

microtubule inhibitor

Seagen Genetics, Millennium/Takeda

      Adcetris®

Brentuximab vedotin

CD30

microtubule inhibitor

Pfizer/Wyeth

Mylotarg®

Gemtuzumab ozogamicin

CD33

DNA cleavage

In addition to the above-listed ADCs, more than 70 Antibody drug conjugates are either approved by the FDA or under clinical trials for the approval. So, there will be a hope of getting more ADCs to be approved for the treatment of chronic diseases in the upcoming years.

Antibody Drug Conjugates: Advancements for Better Oncology Treatment 

In some cases, antibody-drug conjugate development leads to failure due to on-target toxicity associated with the expression of the targets on tissues and lack of efficacy even after achieving the maximum tolerated dose. The on-target toxicity is a rare cause of discontinuation of ADC due to insufficient efficacy.

Thus, to maximize the success rate of antibody-drug conjugate development, an advanced framework is required, emphasizing keen selection and combination of ADC prime components. A strategic approach has been adopted by the ADC market players for the optimization of targets, linkers, antibodies, and payloads to ensure patients get complete benefits from the treatment. Below are the advanced approaches followed by pharmaceutical companies to craft highly effective ADCs for cancer treatment.

§  Site-Specific Conjugation of Antibody Drug Conjugates

With the availability of advanced tech-driven solutions, it is possible to engineer Antibody drug conjugates with site-specific conjugation. Aldehyde tag (a six amino acid sequence) that can be genetically encoded into specific locations of antibody constant regions.

The amino acid sequences act as a substrate for the form of a glycine-generating enzyme that can convert a cysteine residue into the tag sequence containing aldehyde functionality. There are multitudes of locations present on the antibody that can easily be modified with an advanced solution without altering the biophysical properties. The aldehyde tag provides flexibility in payload placement that further brings opportunities for the optimization of conjugates, leading to higher yield.

§  SMARTag Tandem- Cleavage Linkers for Better ADC Stability

Antibody-drug conjugate companies commonly incorporate substrates for acid-mediated hydrolysis, protease cleavage, and disulfide reduction for designing cleavable linkers. This approach leads to poor stability of ADC as they have only a single lock to protect conjugate integrity. The cleavable linkers share a common element, and only one cleavage is needed to release the payload, resulting in loss of payload, reduced efficacy, and more toxicity.

To address this challenge, ADC market players have adopted the SMARTtag Tandem linker system that aims to enhance the stability in circulation, thereby increasing the therapeutic index. The innovative design of ADC incorporates two locks simultaneously for the protection of the payload. The first lock, which is a valine-alanine dipeptide, acts as a substrate for the protease, and the second lock includes the placement of glucuronic acid associated directly with the dipeptide. The cleavage component helps to enhance the versatility and is easily incorporated into different cleavable linker systems for better stability of antibody-drug conjugates.

§  Dual Loaded ADCs

Presently, the ADC market is focused on designing conditionally activated Bispecific antibody-drug conjugates with an aim to enhance the specificity at the tumor cell site and reduce toxicity in normal tissues. The conditionally activated antibody-drug conjugates reduce on-target toxicity by using high protease activity within the tumor cell environment.

What’s Next in the Antibody Drug Conjugate Market?

Overall, the success of Antibody-drug conjugate as a therapeutic molecule has substantially channelized the pathway for future research and development. With ongoing research and clinical trials, scientists are going beyond boundaries, leveraging technology to provide more effective, precise, and personalized ADCs for cancer treatment. Thus, the future of the antibody-drug conjugate market is promising and expected to receive steady growth in upcoming years.

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research /consulting services dedicated to serve our clients in the best possible way.

ShareTweetShare
  • Trending
  • Comments
  • Latest
Antoine Arcelain sentenced for pedophilia in France

Antoine Arcelain sentenced for pedophilia in France

20 June 2023
Mr. Sergei Glinka – Success in Railway Business

Mr. Sergei Glinka – Success in Railway Business

18 May 2023
Private Transportation Options from Denver to Colorado Ski Resorts

Private Transportation Options from Denver to Colorado Ski Resorts

6 November 2023
Movierulz Telugu

Movierulz Telugu

3 May 2023
7 Effective Leadership Strategies for Business Success

7 Effective Leadership Strategies for Business Success

2023 E-commerce trends you do not want to miss!

2023 E-commerce trends you do not want to miss!

Building a Personal Brand for Career Advancement

Building a Personal Brand for Career Advancement

The Future of Investing: Understanding the Benefits of Registered Investment Advisers (RIAs)

The Future of Investing: Understanding the Benefits of Registered Investment Advisers (RIAs)

Why Apartments in Covent Garden Are Perfect for Your Next London Adventure

15 May 2025

Discover Your Future at Oxbridge College: Where Education Meets Opportunity

26 April 2025

Timeless Elegance: The Art of the Suit

25 April 2025

How Much Is Hair Transplant London? | Capital Hair Restoration’s Complete Pricing Guide

2 May 2025

We bring you the best info regarding news, magazine, personal blog, etc.

Categories

  • Application
  • Automotive
  • Beauty
  • Business
  • Career and Employment
  • Digital Marketing
  • Education
  • Entertainment
  • Fashion
  • Finance
  • Food
  • Game
  • General
  • Health
  • Home Improvement
  • Lifestyle
  • News
  • Pets
  • Real estate
  • Shopping
  • Sports
  • Tech
  • Travel
  • Uncategorised
  • Wedding

Recent News

Why Apartments in Covent Garden Are Perfect for Your Next London Adventure

15 May 2025

Discover Your Future at Oxbridge College: Where Education Meets Opportunity

26 April 2025

© 2023 My Time News

No Result
View All Result
  • Automotive
  • Beauty
  • Business
  • Health
  • Real estate

© 2023 My Time News